On Course 2020:

Expertise

Our leadership team holds significant scientific, development and business expertise.

Person's Photo

Executive Leadership Team

Daniel Gold, PhD President & Chief Executive Officer
Dan's Photo

Dr. Gold was appointed President & Chief Executive Officer in April 2010. He joined the Company with approximately 25 years of drug discovery and development experience, most recently as President and Chief Executive Officer of Prospect Therapeutics, a mid-stage oncology company. Prior to his tenure at Prospect, Dr. Gold was founder and Chief Scientific Officer of Favrille, where he was an integral member of a team that advanced the company's lead oncology candidate through a pivotal Phase III clinical trial. He currently serves on the Board of Trustees of the Hope Funds for Cancer Research. Dr. Gold's academic qualifications include Postdoctoral Fellowships at the Dana-Farber Cancer Institute, at the Harvard School of Medicine and the Massachusetts Institute of Technology, Center for Cancer Research. He holds a Ph.D. in Pathology/Immunology from Tufts University, Boston and a bachelor's degree in Biology from the University of California, Los Angeles.

Robert Mass, MD Chief Medical Officer
Robert's Photo

Dr. Mass joined MEI Pharma in December 2010 with more than 20 years of experience as a medical oncologist in both clinical practice and clinical drug development. He held a number of leadership positions at Genentech from 1998 to 2009, most recently as Head of Medical Affairs, BioOncology, a position created to strategically integrate and optimize all of the non-sponsored clinical programs within the company’s oncology portfolio. He also served on the Executive Development Review Committee at Genentech, which was responsible for the review and approval of all sponsored clinical programs across the company’s therapeutic portfolio. Previously he served as clinical science leader for Herceptin® from 1999 to 2002, Tarceva® from 2002 to 2003, and Avastin®, currently the leading oncology therapeutic worldwide, from 2003 to 2007. Prior to joining Genentech, he practiced Hematology and Medical Oncology from 1988 to 1998. Dr. Mass earned his bachelor’s degree in economics from Tufts University and his medical degree from Oregon Health & Science University. He is certified by the American Board of Internal Medicine in both Internal Medicine and Medical Oncology.

Brian Drazba Chief Financial Officer
Brian's Photo

Mr. Drazba joined as Chief Financial Officer in April 2017 with more than 25 years of financial management experience in the healthcare industry. Previously, he served as Vice President of Finance and Chief Financial Officer of Heron Therapeutics, a commercial-stage biotechnology company, from October 2013 to March 2017. From 2009 to 2012, he was Vice President of Finance and Chief Accounting Officer for ISTA Pharmaceuticals, a commercial-stage pharmaceutical company. ISTA Pharmaceuticals was acquired by Bausch + Lomb in June 2012. From 1992 to 2009, Mr. Drazba held various positions of increasing responsibility within Insight Health Corp., most recently as Senior Vice President and Chief Accounting Officer. He began his career at Arthur Andersen & Co., a public accounting firm. Mr. Drazba is a licensed Certified Public Accountant (inactive) in California and received a B.A. degree in accounting from the University of San Diego.

David Urso, JD Senior Vice President Corporate Development, Chief Operating Officer & General Counsel
David's Photo

Mr. Urso joined MEI Pharma in March 2014 with nearly two decades of experience in the life science industry, most recently as Chief Operating Officer and General Counsel at Tioga Pharmaceuticals, a privately held drug development company he co-founded in 2005. Previously, he was a Principal at Forward Ventures, where he was responsible for identifying and developing life science venture capital investments. Prior to joining Forward Ventures in 2002, Mr. Urso was Director of Corporate Development and Legal Affairs at DNA Sciences. Previously, he worked as an attorney in the corporate securities and licensing groups at Wilson Sonsini Goodrich & Rosati LLP and Cooley Godward LLP, after beginning his career as a bench scientist at SmithKline Beecham and the University of Pennsylvania Medical School. Mr. Urso received a J.D. from Harvard Law School and a bachelor's degree in Molecular Biology and Philosophy from Reed College.

Richard Ghalie, MD Senior Vice President, Clinical Development
Richard's Photo

Dr. Ghalie was appointed as Senior Vice President, Clinical Development in March 2016. He is a hematologist and oncologist with more than 20 years of drug development experience at public and private companies. Dr. Ghalie has held several executive positions in the pharmaceutical industry, including serving as Chief Medical Officer at Denovo BioPharma, HemaQuest Pharmaceuticals, Novalar Pharmaceuticals and Favrille, and previously as Vice President at Ligand Pharmaceuticals and NeoRx. He was the medical lead of teams that successfully filed NDAs and MAAs resulting in the approval of four new indications. Previously, he served as Medical Director of the Bone Marrow Transplant Center of Rush University Medical Center. Dr. Ghalie holds a medical degree from the French School of Medicine in Lebanon, a MS from the University Paris XI and a MBA from the University of Washington in Seattle. He has authored or co-authored more than 125 manuscripts, book chapters and scientific publications.

Ofir Moreno, PhD Senior Vice President, Research & Development
Ofir's Photo

Dr. Moreno joined MEI Pharma as Vice President, Pre-Clinical Research in September 2010. He was appointed Vice President, Research & Development in July 2012 and promoted to Senior Vice President, Pharmaceutical Sciences in July 2019. Dr. Moreno has over 25 years of experience in the pharmaceutical industry, including positions of increasing responsibility at Merck, Amgen, Corvas International, and Dendreon. Dr. Moreno earned his bachelor's degree in Biology and Chemistry from Cornell University and his Ph.D. in Organic Chemistry from Harvard University.

Karen Potts, PhD Senior Vice President, Regulatory Affairs
Karen's Photo

Dr. Potts joined as Senior Vice President, Regulatory Affairs in October 2014. Her career spans both the biotechnology and pharmaceutical industries, where she has led global regulatory teams to successfully facilitate the development, approval and life cycle management of therapeutic drugs and biologics. Most recently, Dr. Potts served as Senior Vice President of Regulatory Affairs at Trius Therapeutics until its acquisition by Cubist Pharmaceuticals in September 2013. Previously, she served as Senior Director, Regulatory Policy at Allergan, where she was responsible for global regulatory strategy and policy. Prior to that, Dr. Potts held various strategic positions at Isis Pharmaceuticals, Pfizer and Agouron Pharmaceuticals. She began her career as a post-doctoral fellow at the Center for Disease Control, Division of HIV/AIDS, and subsequently became a Senior Research Scientist in Infectious Disease at Searle. Dr. Potts received a bachelor's degree in Biology from Smith College and a Ph.D. in Microbiology and Immunology from Emory University.

Brian T. Powl Senior Vice President, Marketing
Brian's Photo

Mr. Powl joined MEI Pharma in September 2020 with about 20 years of experience in sales and marketing from leading pharmaceutical and biotech companies, where he developed and implemented commercial product launches and life cycle strategies for multiple hematologic and solid tumor cancers. Most recently, Mr. Powl was Vice President, Global Commercial CAR T lead at Celgene Corporation. Previously, he held other senior level positions at Celgene, including leading their flagship multiple myeloma franchise, and earlier held sales and marketing positions at Novartis Oncology and Centocor, Inc. Mr. Powl holds a BS in Biochemistry from the University of California, San Diego and an MBA in Healthcare Management/Marketing from the Wharton School at the University of Pennsylvania.

David A. Walsey, J.D., LL.M. Vice President, Investor Relations & Corporate Communications
David's Photo

Mr. Walsey joined MEI Pharma as Vice President of Investor Relations and Corporate Communications in February 2018, bringing with him nearly 20 years of experience leading communications initiatives for public biotech companies. He has led investor relations and corporate communications programs at Alder Biopharmaceuticals, Optimer Pharmaceuticals, Sarepta Therapeutics (f/n/a AVI BioPharma), Arena Pharmaceuticals and Maxim Pharmaceuticals. He also has agency experience developing communications strategy and programs for biotechnology clients, having held senior positions at W20, Ruth Group and Noonan Russo. He began his career as an attorney in private practice in New York City. Mr. Walsey holds an LL.M. in Taxation from the New York University School of Law, a J.D. from Brooklyn Law School, and a B.A. from Franklin and Marshall College.

Board of Directors

Christine A. White, MD Non-Executive Chairman

Dr. White has been a director of MEI Pharma since August 2010. She served as Lead Director from January 2013 until she was appointed Chairman of the Board in December 2015. She was with Biogen Idec from 1996 to 2005, most recently as Senior Vice President, Global Medical Affairs, where she played an integral role in the development and commercialization of Rituxan® and Zevalin®. Previously, she served as the Director of Clinical Oncology Research and Chair of the Department of Medicine at Scripps Memorial Hospitals in La Jolla and Encinitas, California. Dr. White served as a member of the board of directors of Arena Pharmaceuticals from 2006 to 2018. She previously served as a member of the board of directors at Genoptix Medical Laboratory, Monogram Biosciences and Pharmacyclics Inc. Dr. White earned her B.A. in Biology and her M.D. from the University of Chicago and is Board certified in both Internal Medicine and Medical Oncology.

Charles V. Baltic III, JD Non-Executive Director

Mr. Baltic has been a director of MEI Pharma since October 2011. Mr. Baltic has been affiliated with Needham & Company, LLC since 2009, as Managing Director and Co-Head of Healthcare until 2019 and as Senior Advisor since 2019. Mr. Baltic also is an Executive Vice President of SIDIS Corp., a life sciences management and investment company, since 2019. Mr. Baltic was a Managing Director and head of the biotechnology practice at CRT Capital Group from 2006 to 2008. From 2001 to 2006, he served as a Managing Director in Healthcare Investment Banking at Wachovia Securities. Prior to Wachovia, he was with Healthcare Investment Banking at Cowen and Company for six years, ultimately serving as a Director. Prior to beginning his investment banking career in 1996, Mr. Baltic practiced corporate and securities law with the firm of Dewy Ballantine, representing numerous healthcare and securities clients. Mr. Baltic previously served as a Director of SIDIS from 2015 - 2019. Mr. Baltic previously served as a Director of the non-profit trade association Life Science Washington (formerly the Washington Biotechnology and Biomedical Association) from 2013 to 2018, and a Director of MedVantage Inc., which was ultimately acquired by IMS Health (now IQVIA) in 2011. Mr. Baltic also previously served as a member of the U.S. Securities and Exchange Commission’s Advisory Committee on Small and Emerging Growth Companies from 2013 to 2015, and as a founding Trustee of the non-profit Hope Funds for Cancer Research from 2007 to 2017, and remains in the Council of Advisors. Mr. Baltic earned his B.A and J.D. degrees from Georgetown University and an M.B.A. degree in finance from the Wharton School of the University of Pennsylvania.

Kevan Clemens, PhD Non-Executive Director

Dr. Clemens was elected as a director in December 2014. He has a long and distinguished career in the pharmaceutical industry, highlighted by 25 years at Labratorios Syntex SA and Hoffman-La Roche in a number of development, sales and marketing positions. As Executive Vice President, Business Director at Roche, he was responsible for the blockbuster Global Oncology franchise, including its strategic plans, development and marketing. Prior to that, he was Vice President, Global Head of Specialty Care, Vice President, Global Head of Project Management and Vice President, Global Head of Clinical Operations for North and South America. Dr. Clemens served on the board of directors of Chelsea Therapeutics International from 2004 until its acquisition by H. Lundbeck A/S in June 2014. He also served on the board of directors of Kosan Biosciences from 2005 to 2008. Dr. Clemens obtained his Ph.D. in Chemistry from the University College London.

Chery L. Cohen Non-Executive Director

Cheryl Cohen has served as a member of our board of directors since April 2020. Ms. Cohen has more than 25 years of leadership experience within the pharmaceutical and biotechnology industries. Ms. Cohen currently serves as President of CLC Consulting, a pharmaceutical and biotechnology consulting firm which she incorporated in 2008, that specializes in new product start-ups and commercialization. Most recently, Ms. Cohen served as Chief Commercial Officer of Medivation, Inc. where she built the company’s commercial organization and lead her team to successfully launch the blockbuster oncology drug, Xtandi®. In 2016, Medivation was acquired by Pfizer Inc. for $14 billion. Prior to joining Medivation, Ms. Cohen spent over 10 years at Johnson & Johnson – most notably as Vice President of the Rheumatology Franchise. In this role, Ms. Cohen was responsible for over $2 billion in annual sales and led multiple commercial entities including marketing, sales, and life cycle management. From June 1998 through November 2007, Ms. Cohen oversaw multiple launches of Remicade® in several indications across a variety of specialties including Gastroenterology and Rheumatology. Ms. Cohen began her career at Solvay Pharmaceuticals in management and sales. Ms. Cohen currently serves on the board of directors of Novus Therapeutics, Inc., Aerpio Pharmaceuticals and NantKwest, all of which are publicly traded companies. She received a B. A. degree from Saint Joseph College.

Frederick W. Driscoll Non-Executive Director

Mr. Driscoll was appointed as a director in February 2018. He currently serves on the board of directors of Cue Biopharma, Cellectar Biosciences, Inc. and NantKwest, Inc. and SmartPharm Therapeutics. He served as the chief financial officer of Flexion Therapeutics, Inc. from 2013 to 2017. Prior to joining Flexion, he was the chief financial officer at Novavax, Inc. from 2009 to 2013. From 2008 to 2009, Mr. Driscoll served as the chief executive officer at Genelabs Technologies, Inc. and from 2007 to 2008 he served as the company's chief financial officer. He was also the chief executive officer of OXiGENE, Inc. from 2000 to 2006. Mr. Driscoll also served as the chairman of the board and audit committee chair at OXiGENE and as a member of the audit committee for Cynapsus Therapeutics, Inc. Mr. Driscoll earned a bachelor's degree in accounting and finance from Bentley University.

Nick Glover, PhD Non-Executive Director

Dr. Glover was appointed as a director in June 2013. He served as President and Chief Executive Officer of Sierra Oncology (NASDAQ: SRRA), a drug development company focused on advancing targeted therapeutics for the treatment of patients with cancer, from July 2014 through May 2020. Prior to joining Sierra, he served as President and Chief Executive Officer of YM BioSciences, an oncology drug development company, from November 2010 until its acquisition by Gilead Sciences for $510 million in February 2013. Previously, Dr. Glover was President and Chief Executive Officer of Viventia Biotech, a biopharmaceutical company involved in the discovery and development of monoclonal antibody-based technologies for the treatment of cancer, which he joined after serving as an investment manager for MDS Capital, a life sciences venture capital firm. Dr. Glover holds a B.Sc. (Hons) in Chemistry from the University of East Anglia, U.K., a M.Sc. in Chemistry from the University of British Columbia, Canada, and a Ph.D. in Chemistry from Simon Fraser University, Canada.

Daniel P. Gold, PhD President & Chief Executive Officer

Dr. Gold was appointed President, Chief Executive Officer and a director in April 2010. He joined the Company with approximately 25 years of drug discovery and development experience, most recently as President and Chief Executive Officer of Prospect Therapeutics, a mid-stage oncology company. Prior to his tenure at Prospect, Dr. Gold was founder and Chief Scientific Officer of Favrille, where he was an integral member of a team that advanced the company's lead oncology candidate through a pivotal Phase III clinical trial. He currently serves on the Board of Trustees of the Hope Funds for Cancer Research. Dr. Gold's academic qualifications include Postdoctoral Fellowships at the Dana-Farber Cancer Institute, at the Harvard School of Medicine and the Massachusetts Institute of Technology, Center for Cancer Research. He holds a Ph.D. in Pathology/Immunology from Tufts University, Boston and a bachelor's degree in Biology from the University of California, Los Angeles.

Tamar Howson Non-Executive Director

Ms. Howson was appointed a director in July 2019. She is a highly experienced business development executive and consultant with more than 30 years of service in the pharmaceutical and biotechnology industries. Ms. Howson currently serves on the board of directors of Organovo Holdings, Inc. and Scientus Pharma, a private company. Between 2009 to 2018 she served on the boards of various other life sciences companies including Actavis plc, Aradigm Corporation, ContraVir Pharmaceuticals, Inc., Cynapsus Therapeutics Inc., Enzymotec PLC, Idenix Pharmaceuticals Inc. and OXiGENE, Inc. From 2009 to 2011, Ms. Howson served as a member of the transaction advisory firm JSB-Partners, providing business development support to life sciences companies. From 2007 to 2008, Ms. Howson served as Executive Vice President, Corporate Business Development at Lexicon Pharmaceuticals, a public biotech company. Prior to joining Lexicon, Ms. Howson served as Senior Vice President, Corporate and Business Development at Bristol-Myers Squibb and SmithKline Beecham plc. Ms. Howson holds an MBA from Columbia University, a M.S. from City University of New York, and a B.S. in Chemical Engineering from the Technion, Israel.

Thomas C. Reynolds, MD, PhD Non-Executive Director

Dr. Reynolds was appointed as a director in February 2013. He is President of Two Paddles Consulting LLC since December 2013, providing consulting services to biotechnology companies. Dr. Reynolds currently serves as an independent director of Trillium Therapeutics Inc. (NASDAQ: TRIL, TSX: TR), an immuno-oncology company, since March 2014. Previosly, he served as Chief Medical Officer of Seattle Genetics from March 2007 until his retirement in February 2013. While at Seattle Genetics, he was responsible for building and leading an integrated clinical development, regulatory and medical affairs organization, highlighted by the development and approval of ADCETRIS®. From 2002 to 2007, Dr. Reynolds served at ZymoGenetics (acquired by Bristol-Myers Squibb in 2010), most recently as Vice President, Medical Affairs, where he oversaw the clinical development and regulatory filing of RECOTHROM®. Previously, he was Vice President, Clinical Affairs at Targeted Genetics, and before that was at Somatix Therapy (acquired by Cell Genesys in 1997). Dr. Reynolds received his M.D. and Ph.D. in Biophysics from Stanford University and a B.A. in Chemistry from Dartmouth College.